JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analyses

被引:19
作者
Kostapanos, Michael S. [1 ]
Elisaf, Moses S. [1 ]
机构
[1] Univ Ioannina, Sch Med, Dept Internal Med, Ioannina 45110, Greece
关键词
Rosuvastatin; Primary prevention; Justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin; Cardiovascular events; Mortality;
D O I
10.4330/wjc.v3.i7.207
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) study was a real breakthrough in primary cardiovascular disease prevention with statins, since it was conducted in apparently healthy individuals with normal levels of low-density lipoprotein cholesterol (LDL-C < 130 mg/dL) and increased inflammatory state, reflected by a high concentration of high-sensitivity C-reactive protein (hs-CRP >= 2 mg/L). These individuals would not have qualified for statin treatment according to current treatment guidelines. In JUPITER, rosuvastatin was associated with significant reductions in cardiovascular outcomes as well as in overall mortality compared with placebo. In this paper the most important secondary analyses of the JUPITER trial are discussed, by focusing on their novel findings regarding the role of statins in primary prevention. Also, the characteristics of otherwise healthy normocholesterolemic subjects who are anticipated to benefit more from statin treatment in the clinical setting are discussed. Subjects at "intermediate" or "high" 10-year risk according to the Framingham score, those who exhibit low post-treatment levels of both LDL-C (< 70 mg/dL) and hs-CRP (< 1 mg/L), who are 70 years of age or older, as well as those with moderate chronic kidney disease (estimated glomerular filtration rate < 60 mL/min every 1.73 m(2)) are anticipated to benefit more from statin treatment. Unlikely other statin primary prevention trials, JUPITER added to our knowledge that statins may be effective drugs in the primary prevention of cardiovascular disease in normocholesterolemic individuals at moderate-to-high risk. Also, statin treatment may reduce the risk of venous thromboembolism and preserve renal function. An increase in physician-reported diabetes represents a major safety concern associated with the use of the most potent statins. (C) 2011 Baishideng. All rights reserved.
引用
收藏
页码:207 / 214
页数:8
相关论文
共 36 条
[1]
Are lipid-lowering guidelines evidence-based? [J].
Abramson, J. ;
Wright, J. M. .
LANCET, 2007, 369 (9557) :168-169
[2]
Venous thromboembolism and atherosclerosis: common denominators or different diseases? [J].
Agnelli, G. ;
Becattini, C. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (09) :1886-1890
[3]
Athyros VG, 2009, HELL J CARDIOL, V50, P89
[4]
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[5]
Brookhart MA, 2010, J CLIN PHARM
[6]
The Cost-Effectiveness of C-Reactive Protein Testing and Rosuvastatin Treatment for Patients With Normal Cholesterol Levels [J].
Choudhry, Niteesh K. ;
Patrick, Amanda R. ;
Glynn, Robert J. ;
Avorn, Jerry .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (07) :784-791
[7]
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[8]
Collins R, 2003, LANCET, V361, P2005
[9]
Eligibility for Statin Therapy by the JUPITER Trial Criteria and Subsequent Mortality [J].
Cushman, Mary ;
McClure, Leslie A. ;
Lakoski, Susan G. ;
Jenny, Nancy S. .
AMERICAN JOURNAL OF CARDIOLOGY, 2010, 105 (01) :77-81
[10]
Rosuvastatin in the Prevention of Stroke Among Men and Women With Elevated Levels of C-Reactive Protein Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) [J].
Everett, Brendan M. ;
Glynn, Robert J. ;
MacFadyen, Jean G. ;
Ridker, Paul M. .
CIRCULATION, 2010, 121 (01) :143-150